Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aridis Pharmaceuticals Inc.

www.aridispharma.com

Latest From Aridis Pharmaceuticals Inc.

After AR-105 VAP Failure, Aridis Looks To AR-301 For Value Justification

Aridis is effectively pulling the plug on AR-105 after the mAb failed in a Phase II ventilator-associated pneumonia trial. It will now focus on its remaining pipeline, led by Phase III asset AR-301.

Clinical Trials Companies

Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.

Commercial Deals

Italfarmaco Options Inhaled Teicoplanin For MRSA Lung Infections

Italfarmaco and Neupharma plan to collaborate on the development of a new inhaled formulation of a Gram-positive targeted antibiotic for MRSA infections in cystic fibrosis.

 

Deals Infectious Diseases

Keeping Track: Some Calm Before The Storm

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aridis Pharmaceuticals Inc.
  • Senior Management
  • Vu L Truong, PhD, CEO
    Fred Kurland, CFO
    Paul Mendelman, MD, Interim CMO
  • Contact Info
  • Aridis Pharmaceuticals Inc.
    Phone: (408) 385-1742
    5941 Optical Ct.
    San Jose, CA 95138
    USA
UsernamePublicRestriction

Register